Lutetium-177 vipivotide tetraxetan (Lu-177 PSMA-617) therapy is an effective treatment for patients with metastatic prostate cancer, although with potential adverse effects to the kidneys, salivary glands, and bone marrow. As a preventative measure for atrisk patients, dosimetry using four SPECT/CT scans is performed with the first cycle of Lu177 therapy. In this work, seven Lu-177 PSMA-617 dosimetry cases from patients treated at Oregon Health & Science University with SPECT scans taken at 4 hours, 24 hours, 48 hours, and 72 hours post-injection were retrospectively analyzed for how omitting each of the scans in performing dosimetry would affect reported absorbed doses to the kidneys, liver, lungs, parotid glands, and tumor.